Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference

MT Newswires Live

Jun 04

Incyte (INCY) and Mirum Pharmaceuticals (MIRM) said Thursday they will present pivotal phase 2 data for zilurgisertib to treat fibrodysplasia ossificans progressiva, or FOP, at the Endocrine Society's annual meeting later this month in Chicago.

"These data add to the growing clinical understanding of zilurgisertib's potential in FOP as Incyte and Mirum continue to advance toward the FDA's priority review PDUFA date" on Sept. 26, said Incyte's chief medical officer Steven Stein.

Incyte shares were 0.7% higher in premarket trading, while Mirum was up 0.2%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2640150860"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640150860\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640150860?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640150860","market":"sh","top_or_hot":-1,"title":"Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference","media":"MT Newswires Live","content":"<html><body><p> Incyte (INCY) and Mirum Pharmaceuticals (MIRM) said Thursday they will present pivotal phase 2 data for zilurgisertib to treat fibrodysplasia ossificans progressiva, or FOP, at the Endocrine Society's annual meeting later this month in Chicago.</p><p>\"These data add to the growing clinical understanding of zilurgisertib's potential in FOP as Incyte and Mirum continue to advance toward the FDA's priority review PDUFA date\" on Sept. 26, said Incyte's chief medical officer Steven Stein.</p><p>Incyte shares were 0.7% higher in premarket trading, while Mirum was up 0.2%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-04 20:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Incyte (INCY) and Mirum Pharmaceuticals (MIRM) said Thursday they will present pivotal phase 2 data for zilurgisertib to treat fibrodysplasia ossificans progressiva, or FOP, at the Endocrine Society's annual meeting later this month in Chicago.</p><p>\"These data add to the growing clinical understanding of zilurgisertib's potential in FOP as Incyte and Mirum continue to advance toward the FDA's priority review PDUFA date\" on Sept. 26, said Incyte's chief medical officer Steven Stein.</p><p>Incyte shares were 0.7% higher in premarket trading, while Mirum was up 0.2%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640150860","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640150860","pubTimestamp":1780577088,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Incyte  and Mirum Pharmaceuticals  said Thursday they will present pivotal phase 2 data for zilurgisertib to treat fibrodysplasia ossificans progressiva, or FOP, at the Endocrine Society's annual meeting later this month in Chicago.\"These data add to the growing clinical understanding of zilurgisertib's potential in FOP as Incyte and Mirum continue to advance toward the FDA's priority review PDUFA date\" on Sept. 26, said Incyte's chief medical officer Steven Stein.Incyte shares were 0.7% higher in premarket trading, while Mirum was up 0.2%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4550":"红杉资本持仓","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗","MIRM":"Mirum Pharmaceuticals, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Incyte和Mirum Pharmaceuticals将在会议上展示新的Zilurgisertib研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1,"INCY":1.5},"content_text":"Incyte (INCY) and Mirum Pharmaceuticals (MIRM) said Thursday they will present pivotal phase 2 data for zilurgisertib to treat fibrodysplasia ossificans progressiva, or FOP, at the Endocrine Society's annual meeting later this month in Chicago.\"These data add to the growing clinical understanding of zilurgisertib's potential in FOP as Incyte and Mirum continue to advance toward the FDA's priority review PDUFA date\" on Sept. 26, said Incyte's chief medical officer Steven Stein.Incyte shares were 0.7% higher in premarket trading, while Mirum was up 0.2%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}